Other languages Atreca, Inc.

Equities

BCEL

US04965G1094

Market Closed - OTC Markets Other stock markets 03:55:16 2024-04-23 pm EDT			5-day change	1st Jan Change
0.08 ^USD	-5.88%		+5.26%	-39.39%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 10	North American Morning Briefing : Traders Await -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atreca, Inc. Announces Board Resignations	Feb. 06
Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	Dec. 26
Atreca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Atreca, Inc. to Continue Exploring Strategic Alternatives	Nov. 13
Investors Remain Cautious Over Fed Moves, Setting Wall Street Up for Lower Open	23-10-20
Top Premarket Gainers	23-10-19
Atreca to Terminate Lease on California Headquarters; Chief Financial Officer Resigns	23-09-21
Atreca, Inc. Appoints Rick Ruiz as the Principal Accounting Officer	23-09-21
Atreca, Inc. Reduces its Workforce by Approximately 40%	23-08-10
Atreca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract	23-06-05
Atreca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Atreca, Inc. Reports Additional Data from Ongoing Phase 1b Trial	23-03-29
Atreca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-29
Atreca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29
Atreca, Xencor to Develop T-Cell Engaging Bispecific Antibody Targeting Solid Tumors	23-02-06
Atreca, Inc. and Xencor, Inc. to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target	23-02-06
Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer	23-01-09
Atreca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10
Atreca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Atreca, Inc.

Equities

BCEL

US04965G1094

Other languages

Filters